Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2003

View Archived Issues

Cholinergic ligands claimed by NeuroSearch patent for CNS disorders

Series of substituted phenylacetamides described in Roche patent

Esters of camptothecins with enhanced anticancer activity described in recent patent

Glaxo patent describes a series of dopamine receptor modulators with antipsychotic properties

Semisynthetic erythromycins prepared by Enanta

NicOx designs treatments for hepatic and portal venous circulation disorders

NeuroSearch, GlaxoSmithKline collaborate on CNS drug development

PARP inhibitors prevent hypoglycemic shock-induced neuronal death

Phase II results support efficacy of NovoSeven in trauma

Eiken will market SARS detection kit in Japan

Exelixis files IND for phase III trial of XL-119

Genmab files to conduct phase I/II HuMax-CD20 trial for NHL

Target enrollment reached in ASCENT trial of DN-101

Zenergen may reduce fat, enhance weight loss

NXC-4720 reduces E. coli contamination in meat

New Zealand approves Thalidomide for multiple myeloma

510(K) clearance for RedLine Alert B. anthracis test kit

The Medicines Company acquires cangrelor from AstraZeneca

European registration dossier for Daxas set for submission in February 2004

Menactra BLA submitted

Lundbeck advances new compounds into phase I

MLN-3897 enters phase I

Dosing starts in phase I study of transdermal PTH

Elan to sell European sales and marketing business to Medeus

ALX-2732 identified as a novel, highly potent and selective human 5-HT1D receptor agonist

Clinical effects of tipifarnib in hematological malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...